Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,725,478
  • Shares Outstanding, K 167,362
  • Annual Sales, $ 957,800 K
  • Annual Income, $ 226,450 K
  • EBIT $ 88 M
  • EBITDA $ 95 M
  • 60-Month Beta 0.47
  • Price/Sales 3.08
  • Price/Cash Flow 24.97
  • Price/Book 3.85

Options Overview Details

View History
  • Implied Volatility 68.12% ( +17.47%)
  • Historical Volatility 87.46%
  • IV Percentile 82%
  • IV Rank 44.86%
  • IV High 127.33% on 04/16/25
  • IV Low 19.95% on 09/19/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 25,540
  • Volume Avg (30-Day) 3,286
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 41,765
  • Open Int (30-Day) 29,812

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.15
  • Number of Estimates 10
  • High Estimate 0.22
  • Low Estimate 0.04
  • Prior Year 0.20
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.08 +58.10%
on 04/22/25
25.23 -11.77%
on 05/16/25
+7.69 (+52.78%)
since 04/16/25
3-Month
13.40 +66.12%
on 04/09/25
25.23 -11.77%
on 05/16/25
+2.22 (+11.08%)
since 02/14/25
52-Week
13.40 +66.12%
on 04/09/25
25.23 -11.77%
on 05/16/25
+7.41 (+49.90%)
since 05/16/24

Most Recent Stories

More News
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 22.26 (+26.48%)
Soleno Therapeutics: Navigating the Path to Profitability with Vykat XR

Summary First-Mover Advantage: Soleno has the market to itself until competition intensifies. High Sales Potential: Projected sales of $876 million by 2030 are highly attractive. Commercial Challenges:...

ACAD : 22.26 (+26.48%)
AARD : 9.89 (+8.80%)
SLNO : 75.01 (-0.08%)
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

AKBA : 2.61 (+2.76%)
STOK : 9.76 (+1.35%)
ACAD : 22.26 (+26.48%)
BIIB : 125.59 (+1.53%)
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...

JAZZ : 108.98 (+2.74%)
ACAD : 22.26 (+26.48%)
AXSM : 107.53 (+0.29%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 22.26 (+26.48%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,958.38 (+0.70%)
STOK : 9.76 (+1.35%)
ACAD : 22.26 (+26.48%)
PHAT : 4.09 (+17.39%)
BIIB : 125.59 (+1.53%)
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 21, 2025 $12 Put had some of the highest implied...

ACAD : 22.26 (+26.48%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 2.03 (+1.50%)
VYGR : 3.30 (+0.61%)
CSTL : 16.75 (+1.64%)
ACAD : 22.26 (+26.48%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 2.03 (+1.50%)
VYGR : 3.30 (+0.61%)
CSTL : 16.75 (+1.64%)
ACAD : 22.26 (+26.48%)
Stocks Rally on Strength in Megacap Tech and Chip Makers

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +1.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.80%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.67%. March E-mini S&P...

GOOGL : 166.19 (+1.36%)
TAP : 56.85 (+1.03%)
BF.B : 36.09 (+1.43%)
$IUXX : 21,427.94 (+0.43%)
ZNM25 : 110-105s (+0.07%)
MSFT : 454.27 (+0.25%)
TSLA : 349.98 (+2.09%)
ESM25 : 5,975.50s (+0.71%)
PHM : 104.41 (+1.60%)
QCOM : 152.50 (-0.07%)
JBL : 167.79 (+0.76%)
AMD : 117.17 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 32.40
2nd Resistance Point 28.81
1st Resistance Point 25.54
Last Price 22.26
1st Support Level 18.68
2nd Support Level 15.09
3rd Support Level 11.82

See More

52-Week High 25.23
Last Price 22.26
Fibonacci 61.8% 20.71
Fibonacci 50% 19.31
Fibonacci 38.2% 17.92
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar